StockMarketWire.com - Indivior said Friday a US court had temporarily blocked rival Alvogen Pine Brook from selling a generic version of the company's opioid addiction treatments.

The temporary restraining order against Alvogen would remain in place until a preliminary injunction hearing due February 7, the company said.

'We will continue to vigorously pursue our infringement cases against Alvogen to protect our SUBOXONE (buprenorphine and naloxone) Sublingual Film patent portfolio, including continuing to pursue the appeal of the U.S. District Court for the District of Delaware's non-infringement decision related to U.S. patents 8,603,514, as well as litigating our recently listed Orange Book patents for SUBOXONE Film,' said Shaun Thaxter, CEO of Indivior.






Story provided by StockMarketWire.com